UY29711A1 - SMALL AGONISTS AND THEIR USES - Google Patents

SMALL AGONISTS AND THEIR USES

Info

Publication number
UY29711A1
UY29711A1 UY29711A UY29711A UY29711A1 UY 29711 A1 UY29711 A1 UY 29711A1 UY 29711 A UY29711 A UY 29711A UY 29711 A UY29711 A UY 29711A UY 29711 A1 UY29711 A1 UY 29711A1
Authority
UY
Uruguay
Prior art keywords
agonists
small
small agonists
pyy3
npy
Prior art date
Application number
UY29711A
Other languages
Spanish (es)
Inventor
Nancy Ann Nardone
Ned Roger Siegel
Rory Francis Finn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW095103474A external-priority patent/TWI310038B/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY29711A1 publication Critical patent/UY29711A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona variantes del péptido PYY3-36 y sus derivados pegilados y composiciones y métodos útiles en el tratamiento de estados modulados por el agonista del receptor Y2 del neuropéptido Y (NPY).The invention provides variants of the PYY3-36 peptide and its pegylated derivatives and compositions and methods useful in the treatment of states modulated by the Y2 receptor neuropeptide agonist (NPY).

UY29711A 2006-01-27 2006-07-31 SMALL AGONISTS AND THEIR USES UY29711A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CL2006000186 2006-01-27
TW095103474A TWI310038B (en) 2005-02-04 2006-01-27 Pyy agonists and uses thereof
PCT/IB2006/000270 WO2006082517A1 (en) 2005-02-04 2006-01-30 Pyy agonists and uses thereof

Publications (1)

Publication Number Publication Date
UY29711A1 true UY29711A1 (en) 2007-08-31

Family

ID=46969902

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29711A UY29711A1 (en) 2006-01-27 2006-07-31 SMALL AGONISTS AND THEIR USES

Country Status (7)

Country Link
AR (1) AR054602A1 (en)
HN (1) HN2006027890A (en)
NL (1) NL1032266C2 (en)
PE (1) PE20070997A1 (en)
SV (1) SV2006002635A (en)
UY (1) UY29711A1 (en)
WO (1) WO2007085887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205971B1 (en) * 2001-09-24 2010-06-30 Imp Innovations Ltd Modification of feeding behavior
US20070027073A1 (en) * 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
PA8660701A1 (en) * 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists

Also Published As

Publication number Publication date
AR054602A1 (en) 2007-06-27
WO2007085887A1 (en) 2007-08-02
HN2006027890A (en) 2010-06-09
PE20070997A1 (en) 2007-11-30
NL1032266C2 (en) 2007-10-09
NL1032266A1 (en) 2007-07-30
SV2006002635A (en) 2010-02-04

Similar Documents

Publication Publication Date Title
DOP2006000025A (en) SMALL AGONISTS AND THEIR USES
ECSP088759A (en) PHARMACEUTICAL COMPOSITIONS
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
CR9428A (en) METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
CL2012001722A1 (en) Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes.
CL2007002649A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO- BENZONITRILE; AND USE FOR THE TREATMENT OF DIABETES.
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
CL2011003085A1 (en) Compounds derived from 1- (piperidin-4-yl) -pyrazole, modulators of protein g-coupled receptor activity, gpr 119; pharmaceutical composition; use of the compounds in the treatment of diabetes or a morbidity associated with said diabetes.
CL2007001749A1 (en) Compound derived from 2-arylamino-4- (heterocycle) aminopyrimidine, c-alpha protein kinase inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of diabetes, cancer, coronary heart disease, atherosclerosis, among others.
CL2009000402A1 (en) Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.
ECSP088315A (en) MODULATORS OF HEXAHYDRO-CYCLLOOCTIL PIRAZOL CANNABINOIDE
ECSP088316A (en) REPLACED MODULATORS OF 3-AMIDO-TETRAHIDRO-INDAZOLIL CANNABINOIDE
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.
ECSP11011021A (en) ANTAGONISTS OF THE VIA HEDGEHOG OF FTALAZINA DISUSTITUIDA
CL2008003546A1 (en) Pyridine derived compounds; preparation procedure; pharmaceutical composition of said compounds; and use in the treatment and / or prophylaxis of type I and / or type II diabetes mellitus.
ES2530670T3 (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same
CL2007002769A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; OBTAINING PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DIABETES.
CL2009000904A1 (en) Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
PA8748501A1 (en) USE OF LXR AGONISTS FOR THE TREATMENT OF OSTEOARTHRITIS
ATE519498T1 (en) COMBINATION OF SOMATOSTATIN ANALOGAS OF DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES
EA200802104A1 (en) APPLICATION OF COMPOSITIONS CONTAINING ANTAGONISTS OF CAPPA-OPIOID RECEPTORS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
UY29711A1 (en) SMALL AGONISTS AND THEIR USES
ECSP088314A (en) HEXAHIDRO-CICLOHEPTAPIRAZOL CANNABINOID MODULATORS
EA200970338A3 (en) HUMAN ERO RECEPTOR AGONISTS, COMPOSITIONS, METHODS AND APPLICATIONS FOR THE PREVENTION OR TREATMENT OF CONDITIONS RELATED TO GLUTOSE INTOLERANCE
HN2006004322A (en) SMALL AGONISTS AND THEIR USES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160830